アレルギー・ワクチンの世界市場

アレルギー・ワクチンの世界市場は2030年までに18億米ドルに達する

2024年に13億米ドルと推定されたアレルギー・ワクチンの世界市場は、2030年には18億米ドルに達し、分析期間2024-2030年のCAGRは6.0％で成長すると予測されます。本レポートで分析したセグメントの1つであるアレルギー性喘息タイプは、CAGR 4.9%を記録し、分析期間終了時には4億7,210万米ドルに達すると予測されます。猫ふけアレルギータイプ」の成長率は、分析期間中CAGR 4.7％と推定されます。

米国市場は3億5,160万米ドルと推定、中国はCAGR 9.2％で成長すると予測

米国のアレルギー・ワクチン市場は、2024年に3億5,160万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 9.2％を辿り、2030年には予測市場規模3億6,720万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.0％と5.8％と予測されています。欧州では、ドイツがCAGR 3.9%で成長すると予測されています。

世界のアレルギー・ワクチン市場- 主要動向と促進要因のまとめ

なぜアレルギー・ワクチンがアレルギー治療の長期展望を再構築しているのか？

アレルギー・ワクチンは、慢性アレルギー疾患との戦いにおいて、一時的な症状の緩和ではなく、根本的な免疫反応を標的とすることで、持続的な症状緩和への道を提供する、革新的なアプローチとして台頭してきています。アレルゲン特異的免疫療法としても知られるこれらのワクチンは、制御された少量のアレルゲンを体内に導入し、免疫系を徐々に減感作します。この過程で、花粉、動物のふけ、昆虫毒、ダニ、特定の食物などの環境誘因に対する過敏症が軽減されます。抗ヒスタミン薬や副腎皮質ステロイド薬は定期的な使用を必要とし、短期的な緩和しかもたらさないが、アレルギー・ワクチンは免疫系を再教育し、持続的な改善をもたらすことを目的としています。先進国でも新興国でもアレルギーが蔓延するにつれ、ヘルスケア専門家は、予防的かつ長期的な効果をもたらす免疫療法にますます注目するようになっています。アレルギー・ワクチンは、喘息や慢性副鼻腔炎などのアレルギー関連合併症のリスクを減少させることができ、さらに魅力的です。この治療法は小児患者においても有望であり、早期に開始すればアレルギー発症の自然な経過を変える可能性があります。患者の意識が高まり、生涯にわたる症状管理に代わる選択肢を求める人が増えるにつれ、アレルギー・ワクチンは単なる治療選択肢としてではなく、意味のある持続的な変化をもたらす疾患修飾ソリューションとして認知されつつあります。

バイオテクノロジーと診断学の革新は、アレルギー・ワクチン開発をどのように前進させているか？

バイオテクノロジーは、アレルギー・ワクチン開発に革命をもたらし、より効果的で、より安全で、より個別化された高度に洗練された製剤を提供する上で、極めて重要な役割を果たしています。従来のアレルギー・ワクチンは、アレルゲンの抽出物全体に基づいており、治療中に強いアレルギー反応を起こす危険性がありました。今日、分子生物学の進歩により、組換えアレルゲンや低アレルギー性変異体の開発が可能になりました。このような技術革新により、個々の免疫プロファイルに合わせたワクチンの開発が可能となり、有効性の向上と治療中止率の減少が実現しました。これと並行して、診断法、特に成分分解診断法（CRD）の進歩により、どのアレルゲンタンパク質が特異的な免疫反応を引き起こすかを特定する臨床医の能力が向上しました。この精度の高さにより、より的を絞った効率的なワクチンレジメンの設計が可能となりました。その他のブレークスルーとしては、免疫寛容を高めるアジュバント、ナノ粒子などの新規デリバリー・プラットフォーム、リンパ内注射や皮下注射などの代替投与ルートなどがあります。これらの技術は、必要な投与回数を減らし、治療期間を短縮することができるため、患者にとってより便利で魅力的なものとなります。さらに、臨床試験や製剤設計における人工知能の統合は、研究者が患者の反応を予測し、最適な治療経路をより早く特定するのに役立っています。このような技術的進歩により、アレルギー・ワクチンはニッチな治療から、主流となる準備が整ったスケーラブルで患者中心の治療へと変貌を遂げつつあります。

アレルギー・ワクチンの世界の需要を拡大している環境およびヘルスケア動向とは？

アレルギー・ワクチンに対する世界の需要の高まりは、環境要因とヘルスケアシステムの進化に強く影響されています。急速な都市化と産業活動の拡大により、空気中のアレルゲンや汚染物質への暴露が強化され、特に都市部におけるアレルギー疾患の有病率の増加に寄与しています。気候変動は、花粉の飛散時期を延ばし、一般的な植物のアレルゲン性を高めることで、アレルギーのパターンをさらに複雑にしています。このような変化により、世界中で何百万人もの人々が、発症の早期化、症状の持続化、アレルギー時期の拡大を招いています。同時に、ヘルスケア・システムは、対症療法から予防的で個別化された治療へと移行しつつあり、これはアレルギー・ワクチン接種の長期的目標と完全に一致しています。国民の意識向上キャンペーンやアレルギー専門医や医療機関による教育普及活動が活発化するにつれ、対症療法にとどまらない治療を求める人が増えています。アジア、ラテンアメリカ、東欧の一部など、中流階級の人口が増加している地域では、ヘルスケアへのアクセスと経済的な余裕が改善するにつれて、先進的な治療に対する需要が顕著に増加しています。一方、世界の医療保険会社や公衆衛生プログラムは、アレルギー免疫療法が長期的に費用対効果が高いことを認識し、保険制度に組み入れ始めています。学校、職場、地域医療機関も、アレルギー管理についてより積極的になり、ワクチン接種のような早期介入戦略を奨励しています。このような広範な環境とヘルスケアのダイナミクスが、アレルギー・ワクチンへの関心を急増させ、現代のアレルギー治療の最前線へと押し上げています。

アレルギー・ワクチン市場の成長を促進する主な要因とは？

アレルギー・ワクチン市場の成長は、科学の進歩、ヘルスケアの優先順位の変化、消費者行動の変化などの組み合わせによって促進されています。主な原動力のひとつは、アレルギー・ワクチンが標準的な薬理学的治療に代わる魅力的な選択肢となり、病気の進行を修正する有効性を裏付ける臨床的エビデンスが増えていることです。このエビデンスは、医師と患者の信頼関係を築き、より広範な採用につながっています。もう一つの重要な要因は、世界的にアレルギー疾患の有病率が増加していることであり、免疫療法の対象人口が大規模かつ着実に拡大しています。ワクチン製剤の開発、特に組換えアレルゲンやアジュバント強化プロトコルの開発により、安全性が大幅に改善され、長期にわたる治療スケジュールの負担が軽減されたことで、免疫療法はより身近で魅力的なものとなっています。さらに、個別化医療やデータ主導の治療計画が重視されるようになってきており、ワクチンが個人の特異的感受性に合わせてカスタマイズされることが多いアレルギー免疫療法のテーラーメイドの性質とシームレスに適合しています。製薬会社やバイオテクノロジー企業も、次世代ワクチンの早期市場投入のため、調査、臨床試験、市場拡大の取り組みに多額の投資を行っています。特に欧州と北米では、規制当局の好意的な政策がイノベーションを促進し、新規参入を促しています。最後に、日常的な対症療法薬の限界に対する意識の高まりと、耐久性がありメンテナンスの手間が少ないソリューションに対する消費者の嗜好の高まりが、多くのアレルギー患者を免疫療法に向かわせる原動力となっています。このような市場促進要因は、免疫療法を専門的な治療選択肢から予防的アレルギー治療の要へと変貌させ、アレルギー・ワクチン市場の持続的成長のための強固な基盤を築きつつあります。

セグメント

アレルギータイプ（アレルギー性喘息タイプ、猫ふけアレルギータイプ、草花過敏症アレルギータイプ、ピーナッツ過敏症アレルギータイプ、季節性アレルギー性鼻炎アレルギータイプ、樹木花粉過敏症アレルギータイプ）、ワクチンタイプ（Cat Allergy Vaccine, House Dust Mite Allergy Vaccine, Injectable MPL Allergy Vaccine, Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine）;用途（HIV Application, Oncology Application, Respiratory Application）;最終用途（Homecare End-use, Hospitals End-use, Specialty Clinics End-use, Other End-use）

調査対象企業の例（注目の34社）

• Afrigen Biologics and Vaccines
• Aimmune Therapeutics
• ALK-Abello A/S
• Allergy Therapeutics
• Allergopharma
• ASIT Biotech
• Bavarian Nordic
• Circassia
• DBV Technologies
• Dermapharm Holding SE
• Desentum Oy
• HAL Allergy B.V.
• HollisterStier Allergy
• LETIPharma
• Merck KGaA
• Panacea Biotec
• Shantha Biotechnics
• Stallergenes Greer
• Torii Pharmaceutical Co., Ltd.
• Zhejiang Wolwo Bio-Pharmaceutical

AIインテグレーション

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Allergy Vaccines Market to Reach US$1.8 Billion by 2030

The global market for Allergy Vaccines estimated at US$1.3 Billion in the year 2024, is expected to reach US$1.8 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Allergic Asthma Type, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$472.1 Million by the end of the analysis period. Growth in the Cat Dander Allergy Type segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$351.6 Million While China is Forecast to Grow at 9.2% CAGR

The Allergy Vaccines market in the U.S. is estimated at US$351.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$367.2 Million by the year 2030 trailing a CAGR of 9.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global Allergy Vaccines Market - Key Trends & Drivers Summarized

Why Are Allergy Vaccines Reshaping the Long-Term Outlook for Allergy Treatment?

Allergy vaccines are emerging as a transformative approach in the battle against chronic allergic diseases, offering a path to sustained symptom relief by targeting the underlying immune response rather than temporarily alleviating symptoms. Also known as allergen-specific immunotherapy, these vaccines introduce small, controlled amounts of allergens into the body to gradually desensitize the immune system. Over time, this process reduces hypersensitivity to environmental triggers such as pollen, animal dander, insect venom, dust mites, and certain foods. Unlike antihistamines or corticosteroids that require regular use and offer only short-term relief, allergy vaccines aim to retrain the immune system and offer lasting improvements-often extending beyond the treatment period. As allergies become more prevalent in both developed and emerging regions, healthcare professionals are increasingly turning to immunotherapeutic strategies that provide preventive, long-term benefits. The ability of allergy vaccines to reduce the risk of allergy-related complications, such as asthma or chronic sinusitis, adds further appeal. The therapy has also shown promise in pediatric patients, offering potential to alter the natural course of allergy development when started early. As patient awareness grows and more individuals seek alternatives to lifelong symptom management, allergy vaccines are gaining recognition not just as a treatment option, but as a disease-modifying solution that offers meaningful and durable change.

How Are Innovations in Biotechnology and Diagnostics Advancing Allergy Vaccine Development?

Biotechnology is playing a pivotal role in revolutionizing allergy vaccine development, bringing forward highly refined formulations that are more effective, safer, and personalized. Traditional allergy vaccines were based on whole allergen extracts, which carried the risk of strong allergic reactions during treatment. Today, advances in molecular biology have enabled the development of recombinant allergens and hypoallergenic variants-engineered proteins that preserve immunological benefits while minimizing adverse effects. These innovations have made it possible to tailor vaccines to individual immune profiles, thereby improving efficacy and reducing treatment dropout rates. In parallel, progress in diagnostics-particularly component-resolved diagnostics (CRD)-has enhanced clinicians’ ability to pinpoint which allergen proteins trigger specific immune responses. This precision allows for the design of more targeted and efficient vaccine regimens. Other breakthroughs include adjuvants that boost immune tolerance, novel delivery platforms such as nanoparticles, and alternative administration routes like intralymphatic and epicutaneous injections. These techniques can reduce the number of doses required and shorten the duration of therapy, making it more convenient and appealing for patients. Additionally, the integration of artificial intelligence in clinical trials and formulation design is helping researchers predict patient responses and identify optimal treatment paths faster. These technological strides are reshaping the allergy vaccine landscape by elevating it from a niche treatment to a scalable, patient-centered therapy poised for mainstream adoption.

What Environmental and Healthcare Trends Are Expanding Global Demand for Allergy Vaccines?

The rising global demand for allergy vaccines is strongly influenced by environmental factors and healthcare system evolution. Rapid urbanization and growing industrial activity have intensified exposure to airborne allergens and pollutants, contributing to the increasing prevalence of allergic conditions, particularly in urban populations. Climate change has further complicated allergy patterns by prolonging pollen seasons and increasing the allergenic potential of common plants. These shifts are leading to earlier onset, more persistent symptoms, and an expanded allergy season for millions of individuals worldwide. At the same time, healthcare systems are transitioning from symptom-based treatment toward preventive and personalized care, which aligns perfectly with the long-term objectives of allergy vaccination. As public awareness campaigns and educational outreach by allergists and medical organizations increase, more people are seeking therapies that go beyond symptomatic relief. In regions with growing middle-class populations-such as parts of Asia, Latin America, and Eastern Europe-there is a notable rise in demand for advanced treatments as healthcare access and affordability improve. Meanwhile, global health insurers and public health programs are starting to include allergy immunotherapy in coverage plans, recognizing its cost-effectiveness over time. Schools, workplaces, and community health organizations are also becoming more proactive about allergy management, further encouraging early intervention strategies like vaccination. These broad environmental and healthcare dynamics are fueling a surge in interest for allergy vaccines, pushing them to the forefront of modern allergy care.

What Are the Key Factors Driving Growth in the Allergy Vaccines Market?

The growth of the allergy vaccines market is being fueled by a combination of scientific progress, shifting healthcare priorities, and changing consumer behavior. One of the primary drivers is the growing body of clinical evidence supporting the efficacy of allergy vaccines in modifying disease progression, which makes them an attractive alternative to standard pharmacological treatments. This evidence has helped build trust among physicians and patients, leading to broader adoption. Another important factor is the increasing prevalence of allergic conditions globally, which has created a large and steadily expanding target population for immunotherapy. Advances in vaccine formulation, particularly the development of recombinant allergens and adjuvant-enhanced protocols, have significantly improved safety and reduced the burden of long treatment schedules, making the therapy more accessible and appealing. Additionally, the rising emphasis on personalized medicine and data-driven treatment plans fits seamlessly with the tailored nature of allergy immunotherapy, where vaccines are often customized to an individual’s specific sensitivities. Pharmaceutical and biotech companies are also investing heavily in research, clinical trials, and market expansion efforts to bring next-generation allergy vaccines to market faster. Favorable regulatory policies, especially in Europe and North America, have facilitated innovation and encouraged new entrants. Lastly, increased awareness of the limitations of daily symptom control medications-along with a growing consumer preference for durable, low-maintenance solutions-is driving many allergy sufferers to pursue immunotherapy. These interconnected drivers are laying a strong foundation for sustained growth in the allergy vaccines market, transforming it from a specialist treatment option to a cornerstone of preventive allergy care.

SCOPE OF STUDY:

The report analyzes the Allergy Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Allergy Type (Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type, Tree Pollen Hypersensitivity Allergy Type); Vaccine Type (Cat Allergy Vaccine, House Dust Mite Allergy Vaccine, Injectable MPL Allergy Vaccine, Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine); Application (HIV Application, Oncology Application, Respiratory Application); End-Use (Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Afrigen Biologics and Vaccines
• Aimmune Therapeutics
• ALK-Abello A/S
• Allergy Therapeutics
• Allergopharma
• ASIT Biotech
• Bavarian Nordic
• Circassia
• DBV Technologies
• Dermapharm Holding SE
• Desentum Oy
• HAL Allergy B.V.
• HollisterStier Allergy
• LETIPharma
• Merck KGaA
• Panacea Biotec
• Shantha Biotechnics
• Stallergenes Greer
• Torii Pharmaceutical Co., Ltd.
• Zhejiang Wolwo Bio-Pharmaceutical

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Allergy Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Allergy Burden Spurs Demand for Preventive and Long-Term Allergy Vaccine Solutions
  • Advancements in Recombinant and Molecular-Based Allergy Vaccines Propel Growth in Precision Immunotherapy
  • Here's How Growing Support for Disease-Modifying Therapies Strengthens the Business Case for Allergy Vaccines
  • Expansion of Pediatric Allergy Immunization Programs Broadens the Addressable Market Opportunity
  • Rising Public and Clinical Awareness of Allergen Desensitization Drives Adoption in High-Risk Populations
  • Shift Toward Personalized Medicine Throws the Spotlight on Tailored Allergy Vaccine Regimens
  • Here's the Story: Biotech Collaborations and Academic-Industry Partnerships Fuel Pipeline Expansion
  • Emergence of Adjuvant Technologies Enhances Efficacy and Safety Profile of Next-Gen Allergy Vaccines
  • Growing Demand for Non-Invasive and Alternative Delivery Methods Drives Research Into Novel Vaccine Formats
  • Climate Change-Linked Allergen Proliferation Expands Use-Cases for Region-Specific Allergy Vaccines
  • Rising Incidence of Food and Inhalant Allergies Throws the Spotlight on Preventive Vaccine Innovations
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Allergy Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Allergy Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Allergy Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Allergy Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Allergic Asthma Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Allergic Asthma Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Allergic Asthma Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Cat Dander Allergy Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Cat Dander Allergy Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Cat Dander Allergy Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Grass Pollen Hypersensitivity Allergy Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Grass Pollen Hypersensitivity Allergy Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Grass Pollen Hypersensitivity Allergy Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Peanut Hypersensitivity Allergy Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Peanut Hypersensitivity Allergy Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Peanut Hypersensitivity Allergy Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Seasonal Allergic Rhinitis Allergy Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Seasonal Allergic Rhinitis Allergy Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Seasonal Allergic Rhinitis Allergy Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Tree Pollen Hypersensitivity Allergy Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Tree Pollen Hypersensitivity Allergy Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Tree Pollen Hypersensitivity Allergy Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Peanut Allergy Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Peanut Allergy Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Peanut Allergy Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Ragweed Allergy Immunotherapy Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Ragweed Allergy Immunotherapy Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Ragweed Allergy Immunotherapy Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Cat Allergy Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Cat Allergy Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Cat Allergy Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for House Dust Mite Allergy Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for House Dust Mite Allergy Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for House Dust Mite Allergy Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Injectable MPL Allergy Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Injectable MPL Allergy Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Injectable MPL Allergy Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for HIV Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for HIV Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for HIV Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Respiratory Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Respiratory Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: World 16-Year Perspective for Respiratory Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Homecare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Homecare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: World 16-Year Perspective for Homecare End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: World 16-Year Perspective for Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 56: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 57: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Allergy Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 59: USA Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: USA 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: USA 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 65: USA Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: USA Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: USA 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 68: USA Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: USA Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: USA 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: Canada 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Canada 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: Canada 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 80: Canada Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Canada Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: Canada 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• JAPAN
  • Allergy Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: Japan 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: Japan 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Japan Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: Japan 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 92: Japan Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Japan Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: Japan 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CHINA
  • Allergy Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 95: China Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: China 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: China 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 101: China Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: China Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: China 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 104: China Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: China Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: China 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• EUROPE
  • Allergy Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Allergy Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Allergy Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: Europe 16-Year Perspective for Allergy Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: Europe 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: Europe 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 116: Europe Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Europe Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: Europe 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 119: Europe Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Europe Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: Europe 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• FRANCE
  • Allergy Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 122: France Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: France 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 125: France Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: France 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 128: France Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: France Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: France 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 131: France Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: France Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: France 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• GERMANY
  • Allergy Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Germany 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Germany 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 140: Germany Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Germany Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Germany 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 143: Germany Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Germany Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Germany 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: Italy 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 149: Italy Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: Italy 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 152: Italy Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Italy Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: Italy 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 155: Italy Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Italy Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: Italy 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Allergy Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 158: UK Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: UK 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 161: UK Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: UK 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 164: UK Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: UK Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: UK 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 167: UK Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: UK Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: UK 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: Spain 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 173: Spain Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: Spain 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 176: Spain Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Spain Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: Spain 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 179: Spain Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Spain Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: Spain 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: Russia 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 185: Russia Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: Russia 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 188: Russia Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Russia Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: Russia 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 191: Russia Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Russia Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: Russia 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: Rest of Europe 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Europe Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: Rest of Europe 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Europe Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: Rest of Europe 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Allergy Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Allergy Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Allergy Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 16-Year Perspective for Allergy Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Asia-Pacific Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 217: Asia-Pacific 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Asia-Pacific Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 220: Asia-Pacific 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Allergy Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 223: Australia 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 224: Australia Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 226: Australia 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 227: Australia Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Australia Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 229: Australia 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 230: Australia Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Australia Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 232: Australia 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• INDIA
  • Allergy Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 233: India Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 235: India 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 236: India Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: India Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 238: India 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 239: India Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: India Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 241: India 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 242: India Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: India Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 244: India 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 247: South Korea 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 250: South Korea 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 251: South Korea Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: South Korea Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 253: South Korea 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 254: South Korea Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: South Korea Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 256: South Korea 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Rest of Asia-Pacific Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 265: Rest of Asia-Pacific 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Rest of Asia-Pacific Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 268: Rest of Asia-Pacific 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Allergy Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Allergy Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Allergy Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 271: Latin America 16-Year Perspective for Allergy Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 274: Latin America 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 277: Latin America 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 278: Latin America Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Latin America Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 280: Latin America 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 281: Latin America Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Latin America Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 283: Latin America 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 286: Argentina 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 289: Argentina 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 290: Argentina Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Argentina Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 292: Argentina 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 293: Argentina Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Argentina Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 295: Argentina 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 298: Brazil 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 301: Brazil 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 302: Brazil Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Brazil Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 304: Brazil 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 305: Brazil Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Brazil Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 307: Brazil 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 310: Mexico 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 313: Mexico 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 314: Mexico Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Mexico Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 316: Mexico 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 317: Mexico Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Mexico Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 319: Mexico 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 325: Rest of Latin America 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Rest of Latin America Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 328: Rest of Latin America 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Rest of Latin America Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 331: Rest of Latin America 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Allergy Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Allergy Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Allergy Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 334: Middle East 16-Year Perspective for Allergy Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 337: Middle East 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 340: Middle East 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 341: Middle East Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Middle East Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 343: Middle East 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 344: Middle East Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Middle East Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 346: Middle East 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 349: Iran 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 350: Iran Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 352: Iran 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 353: Iran Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Iran Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 355: Iran 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 356: Iran Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Iran Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 358: Iran 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 361: Israel 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 362: Israel Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 364: Israel 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 365: Israel Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Israel Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 367: Israel 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 368: Israel Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Israel Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 370: Israel 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 376: Saudi Arabia 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Saudi Arabia Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 379: Saudi Arabia 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Saudi Arabia Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 382: Saudi Arabia 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 385: UAE 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 386: UAE Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 388: UAE 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 389: UAE Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: UAE Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 391: UAE 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 392: UAE Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: UAE Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 394: UAE 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 400: Rest of Middle East 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Rest of Middle East Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 403: Rest of Middle East 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Rest of Middle East Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 406: Rest of Middle East 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AFRICA
  • Allergy Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Allergy Vaccines by Allergy Type - Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 409: Africa 16-Year Perspective for Allergy Vaccines by Allergy Type - Percentage Breakdown of Value Sales for Allergic Asthma Type, Cat Dander Allergy Type, Grass Pollen Hypersensitivity Allergy Type, Peanut Hypersensitivity Allergy Type, Seasonal Allergic Rhinitis Allergy Type and Tree Pollen Hypersensitivity Allergy Type for the Years 2014, 2025 & 2030
  • TABLE 410: Africa Recent Past, Current & Future Analysis for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for Allergy Vaccines by Vaccine Type - Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 412: Africa 16-Year Perspective for Allergy Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Peanut Allergy Vaccine, Ragweed Allergy Immunotherapy Vaccine, Cat Allergy Vaccine, House Dust Mite Allergy Vaccine and Injectable MPL Allergy Vaccine for the Years 2014, 2025 & 2030
  • TABLE 413: Africa Recent Past, Current & Future Analysis for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Africa Historic Review for Allergy Vaccines by Application - HIV Application, Oncology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 415: Africa 16-Year Perspective for Allergy Vaccines by Application - Percentage Breakdown of Value Sales for HIV Application, Oncology Application and Respiratory Application for the Years 2014, 2025 & 2030
  • TABLE 416: Africa Recent Past, Current & Future Analysis for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 417: Africa Historic Review for Allergy Vaccines by End-Use - Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 418: Africa 16-Year Perspective for Allergy Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare End-Use, Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION